Trials / Unknown
UnknownNCT05097664
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Isfahan University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.
Detailed description
Investigators will achieved the following data from the participants: 1. Demographic 2. Past medical/habitual history 3. COVID-19 status and related risk factors 4. Mucormycosis status and related risk factors 5. Ocular examination and imaging 6. Follow-up
Conditions
Timeline
- Start date
- 2021-08-23
- Primary completion
- 2021-11-21
- Completion
- 2022-01-20
- First posted
- 2021-10-28
- Last updated
- 2021-10-28
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT05097664. Inclusion in this directory is not an endorsement.